The Adverse Drug Reactions Advisory Committee or ADRAC is a subcommittee of the Australian Drug Evaluation Committee (ADEC) which monitors the safety of medicines in Australia. ADRAC evaluates reports from the Adverse Drug Reactions Unit of the Therapeutic Goods Administration (TGA), which administers the adverse drug reaction (ADR) reporting system in Australia, and may make recommendations regarding the medication including withdrawal of medications from the market. ADRAC also publishes the Australian Adverse Drug Reactions Bulletin to raise awareness of medication safety issues and ADR reports.

From Wikipedia under the GNU Free Documentation License
Sun Jul 12 16:40:17 2009

 Adverse Drug Reaction Monitoring | Pharmainfo.net
pharmainfo.net
Adverse Drug Reaction Monitoring | Pharmainfo.net

zarrinfaria

ue, 24 Mar 2009 06:45:53 GM

ADRs are reported to the . Adverse drug reactions advisory committee. or other appropriate regulatory authority and /or to the manufacturer in the case of trial or non-marketed drugs. In-house documentation of . adverse drug reactions. is ...

Kiran Babu Tiwari: Biosafety
kiranbabutiwari.blogspot.com
Kiran Babu Tiwari: Biosafety

Kiran Babu Tiwari

ue, 18 Aug 2009 12:44:00 GM

These concerns were examined by a . committee. of National Academy of Sciences ( U.S.A. ) in 1974. As a consequence, the National Institute of Health, U.S.A. (NIH) established the Recombinant . Advisory Committee. (RAC) in 1974. ... Cartagena Protocol on Biosafety to the Convention on Biological Diversity has been designed to cover the transboundary movement, trails it, handling and use of all living modified organisms that may have . adverse. effects on the conservation and ...

TGA Australia Urgent recall Lumiracoxib PREXIGE medicine. Visit ...
medicineroom.wordpress.com
TGA Australia Urgent recall Lumiracoxib PREXIGE medicine. Visit ...

medicineroom

Sun, 12 Aug 2007 05:10:11 GM

The TGA and its expert . advisory committee. , the . Adverse Drug Reactions Advisory Committee. (ADRAC), have urgently investigated these reports. ADRAC has today recommended the cancellation of the registration of Lumiracoxib due to the ...

0006 gif
tga.gov.au
0006 gif
325px x 381px | 10.10kB

[source page]

in the class of COX 2 inhibitors to be marketed in Australia From the start of marketing in October 1999 to April 2000 ADRAC has received 919 reports of suspected adverse reactions Adverse Reaction Profile for Celecoxib The chart shows the proportion of reaction terms in the various categories Numbers of more common terms are shown Where more than one

nurofen jpg
auspharmlist.net.au
nurofen jpg
41px x 82px | 24.40kB

[source page]

Ibuprofen to remain open 23 02 2007 Outcomes of a 12 month safety review of general NSAIDs conducted by the Therapeutic Goods Administration TGA in consultation with the Adverse Drug Reactions Advisory Committee adrac the

adrac gif
mja.com.au
adrac gif
79px x 80px | 0.33kB

[source page]

Movement disorders with selective serotonin reuptake inhibitors Adverse Drug Reactions Advisory Committee